Moderna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
A ‘sell-the-news reaction’? The experimental treatment helped prevent the return of cancer or death in melanoma patients by 42% after two years.
This is a summary aggregated from MarketWatch. Read the complete article on the original site:
Read full article at MarketWatch
